
A Landmark Trial Establishes The Safety Of Immunotherapy In Type 1 Diabetes
Nearly 5% of the population in the United States suffers from type 1 diabetes; an autoimmune disorder where the body’s immune system specifically fails to recognize pancreas’ insulin producing beta cells and mistakenly attacks them.
In the absence of sure shot treatment and the dearth of studies on immunotherapy, Dr Mohammad Alhadj Ali, Cardiff University School of Medicine, U.K., and Mark Peakman, professor of clinical immunology at King's College London, conducted a study on the possi
Read More